仙灵骨葆胶囊治疗绝经后骨质疏松的系统评价

A systematic evaluation on Xianlinggubao capsule for postmenopausal osteoporosis

[目的]系统评价仙灵骨葆胶囊(XLGB)治疗绝经后骨质疏松(PMOP)的疗效和安全性。[方法]检索Cochrane图书馆,PubMed,EMbase,CBM,CNKI和VIP数据库,收集并评价XLGB治疗PMOP的随机对照试验,采用RevMan5.0进行分析。[结果]共纳入7篇文献,3篇采用随机数字表。结果显示:治疗3个月XLGB组提高L2-L4腰椎、股骨颈骨密度效果优于单独钙剂组,治疗3、6个月XLGB组提高Ward’s三角、股骨大粗隆骨密度效果优于对照组,治疗6、12个月XLGB组提高血清雌二醇(E2)效果优于对照组;治疗6、12个月后西药组提高血清E2的效果优于XLGB组;治疗6个月后"XLGB+西药+钙剂"组提高腰椎、股骨颈骨密度的效果优于"西药+钙剂"组。XLGB无严重不良事件的报道。[结论]现有临床研究证据表明,与单纯使用钙剂组相比,XLGB可提高PMOP骨密度和E2。

[Objective] To assess the efficacy and safety of Xianling Gubao Capsule（XLGB） in treating postmenopausal osteoporosis（PMOP）.[Methods] All data of the clinical trials of XLGB for postmenopausal osteoporosis were searched from Cochrane library,PubMed,EMbase,CBM,CNKI and VIP.To evaluate the methodological quality of included studies,the RevMan 5.0 was used for data analysis.[Results] A total of 7 trials were included,only 3 trials used random number table.The improvement of L2-L4 bone mineral density（BMD）,femoral neck BMD,Ward＇s triangle BMD and femoral greater trochanter BMD on 3 months in XLGB group were better than calcium group,the improvement of Ward＇s triangle BMD and femoral greater trochanter BMD on 6 months in XLGB group were better than calcium group,the improvement of serum oestradiol on 6 and 12 months in XLGB group was better than calcium group.The improvement of serum oestradiol on 6 and 12 months in Western medicine group was better than XLGB group.The improvement of L2-L4 BMD and femoral neck BMD on 6 months in XLGB plus Western medicine group was better than Western medicine group.No significant adverse drug reactions of XLGB were reported.[Conclusion] The evidence currently available showed that XLGB may improve BMD and serum oestradiol compared with calcium group.However,because of the small sample of included trials,the conclusions need to be interpreted cautiously,and more well-designed,high-quality RCTs need to be performed.